IGK Suppresses Keloid Fibroblast Activation Through Modulation of MDM2 Expression and p53 Signaling
Cell Biology International · 2026-10 · 50 (10)
DOI: 10.1002/cbin.70213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, online erschienen am 24.09.2026. Verfasst von Ziqing Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Burns, Wuhan Third Hospital (Tongren Hospital of WuHan University), Wuhan, China. Hauptthemen laut MEDLINE: Keloid, Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53, Fibroblasts. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, Wuhan Municipal Health Commission's 2023 Youth Talent Support Program "Morning Star Plan".
Abstract (Originalsprache)
Keloids are intricate fibroproliferative disorders characterized by sustained fibroblast activation, excessive deposition of extracellular matrix, and dysregulated wound‐healing responses. This study explored the therapeutic effects and underlying mechanisms of Isoginkgetin (IGK) in keloid fibroblasts (KFbs) and a human keloid xenograft model. Our findings indicated that MDM2 expression was elevated in clinical keloid specimens, and IGK treatment inhibited KFbs proliferation and migration while inducing cell cycle arrest and apoptosis. Mechanistically, IGK downregulated MDM2 expression at the transcriptional level and was associated with the modulation of the MDM2/p53 signaling axis. LiP‐MS and molecular docking analyses identified eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) as a potential IGK‐associated protein, suggesting that EEF1A1 may play a role in IGK‐mediated regulation of MDM2 expression. Moreover, transcriptomic analysis of xenograft tissues combined with serum multicytokine profiling demonstrated that IGK treatment modulated inflammation‐associated signatures, including those related to TNF signaling pathways, within the xenograft model. In vivo, administration of IGK resulted in a reduction in volume, collagen deposition, and α‐SMA expression in established human keloid xenografts. Taken together, these findings indicate that IGK exerts anti‐keloid effects by modulating the MDM2/p53 signaling axis and inflammation‐associated pathways, underscoring its potential as a therapeutic candidate for keloid treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Burns, Wuhan Third Hospital (Tongren Hospital of WuHan University), Wuhan, China.
- Hubei Provincial Clinical Medical Research Center for Burns, Wuhan, China.
- Second Clinical College, Wuhan University, Wuhan, China.
- Department of Urology, Wuhan Third Hospital (Tongren Hospital of WuHan University), Wuhan, China.
- School of Medicine, Wuhan University of Science and Technology, Wuhan, China.
ORCID-Profile: Shuhua Liu, Junhui Xu, Siyu Zhang
Förderung
- Natural Science Foundation of Hubei Province
- Wuhan Municipal Health Commission's 2023 Youth Talent Support Program "Morning Star Plan"
Zitieren
APA
Ye, Z., Liu, F., Tang, H., Wang, X., Liu, S., Ruan, Q., Xu, J., Dong, M., Xie, W., & Zhang, S. (2026). IGK Suppresses Keloid Fibroblast Activation Through Modulation of MDM2 Expression and p53 Signaling. Cell Biology International, 50(10). https://doi.org/10.1002/cbin.70213
Vancouver
Ye Z, Liu F, Tang H, Wang X, Liu S, Ruan Q, et al. IGK Suppresses Keloid Fibroblast Activation Through Modulation of MDM2 Expression and p53 Signaling. Cell Biology International. 2026;50(10). doi:10.1002/cbin.70213
BibTeX
@article{Ye2026,
author = {Ye, Ziqing and Liu, Feng and Tang, Huancheng and Wang, Xiaoshuang and Liu, Shuhua and Ruan, Qiongfang and Xu, Junhui and Dong, Maolong and Xie, Weiguo and Zhang, Siyu},
title = {IGK Suppresses Keloid Fibroblast Activation Through Modulation of MDM2 Expression and p53 Signaling},
journal = {Cell Biology International},
year = {2026},
volume = {50},
number = {10},
doi = {10.1002/cbin.70213}
}
EUVIMED